ZA202007955B - Ccr5 inhibitor for use in treating cancer - Google Patents

Ccr5 inhibitor for use in treating cancer

Info

Publication number
ZA202007955B
ZA202007955B ZA2020/07955A ZA202007955A ZA202007955B ZA 202007955 B ZA202007955 B ZA 202007955B ZA 2020/07955 A ZA2020/07955 A ZA 2020/07955A ZA 202007955 A ZA202007955 A ZA 202007955A ZA 202007955 B ZA202007955 B ZA 202007955B
Authority
ZA
South Africa
Prior art keywords
treating cancer
ccr5 inhibitor
ccr5
inhibitor
cancer
Prior art date
Application number
ZA2020/07955A
Other languages
English (en)
Inventor
Oliver Hartley
Robin Ewart Offord
Original Assignee
ORION Biotechnology Switzerland Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ORION Biotechnology Switzerland Sarl filed Critical ORION Biotechnology Switzerland Sarl
Publication of ZA202007955B publication Critical patent/ZA202007955B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2020/07955A 2018-05-28 2020-12-18 Ccr5 inhibitor for use in treating cancer ZA202007955B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677114P 2018-05-28 2018-05-28
US201962792600P 2019-01-15 2019-01-15
PCT/IB2019/054350 WO2019229616A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
ZA202007955B true ZA202007955B (en) 2022-06-29

Family

ID=67480241

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/07955A ZA202007955B (en) 2018-05-28 2020-12-18 Ccr5 inhibitor for use in treating cancer

Country Status (11)

Country Link
US (1) US20210205411A1 (enExample)
EP (1) EP3813870B1 (enExample)
JP (2) JP7319020B2 (enExample)
KR (1) KR20210016398A (enExample)
CN (1) CN112469429B (enExample)
AU (1) AU2019276939A1 (enExample)
BR (1) BR112020024328A2 (enExample)
CA (1) CA3101556A1 (enExample)
MX (1) MX2020012782A (enExample)
WO (1) WO2019229616A1 (enExample)
ZA (1) ZA202007955B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729023A (zh) * 2019-04-01 2022-07-08 西托戴恩股份有限公司 阻断癌症转移或增强由dna损伤化学疗法诱导的细胞死亡的抗ccr5药剂和治疗方法
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2024146707A1 (en) * 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) * 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
EP3693041A1 (en) * 2011-06-13 2020-08-12 TLA Targeted Immunotherapies AB Treating cancer
HK1209673A1 (en) * 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US20180289689A1 (en) * 2014-10-27 2018-10-11 Ruprecht-Karls-Universität Heidelberg Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Also Published As

Publication number Publication date
JP7319020B2 (ja) 2023-08-01
AU2019276939A1 (en) 2021-01-21
EP3813870B1 (en) 2023-11-15
US20210205411A1 (en) 2021-07-08
MX2020012782A (es) 2021-04-28
CA3101556A1 (en) 2019-12-05
BR112020024328A2 (pt) 2021-02-23
JP2021525770A (ja) 2021-09-27
EP3813870C0 (en) 2023-11-15
CN112469429B (zh) 2025-02-14
KR20210016398A (ko) 2021-02-15
EP3813870A1 (en) 2021-05-05
JP2023134704A (ja) 2023-09-27
CN112469429A (zh) 2021-03-09
WO2019229616A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
SG11202105747XA (en) Csf1r inhibitors for use in treating cancer
SG11202104356VA (en) Bt1718 for use in treating cancer
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
ZA202006627B (en) Methods and compositions for treating cancer
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
SG10201913331VA (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
PT3293201T (pt) Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
SG11202012435UA (en) Compositions and methods for treating cancer
SMT202100207T1 (it) Inibitori della farnesiltransferasi per il trattamento del cancro
GB201702160D0 (en) Inhibitors for use in therapy
IL276668A (en) Thioredoxin reductase inhibitors for use in the treatment of cancer
IL280830A (en) Bracelets for use in cancer treatment methods
IL282948B2 (en) Cancer treatment preparations and methods
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
IL286949A (en) Mesitantan for use in the treatment of portopulmonary hypertension
IL285538A (en) Combined therapies for use in cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
PT3813832T (pt) Compostos para utilização na prevenção ou tratamento de cancro
HK40060258A (en) Bt1718 for use in treating cancer
EP3131550A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment